Interaction Checker

Interações de Pasireotida

Pasireotida (Signifor, Signifor LAR) tem 136 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 0; moderadas: 135; leves: 1; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações moderadas (135)

  • AcebutololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • AlfuzosinaalfabloqueadorModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • AmiodaronaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Amitriptilinaantidepressivo tricíclicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Anagrelidamedicamento que prolonga o intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Anlodipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Anlodipino + atorvastatinabloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Anlodipino + benazeprilbloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Anlodipino + olmesartanabloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Anlodipino + valsartanabloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • AsenapinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • AtenololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Atenolol + clortalidonabetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Azelastina + fluticasonaanti-histamínicoModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • Azitromicinaantibiótico macrolídeoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • BeclometasonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • BetametasonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • BetaxololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • BisoprololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Bisoprolol + hidroclorotiazidabetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Brimonidina + timololagonista alfa-adrenérgicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Bromocriptinaagonista da dopaminaModerada

    Bromocriptine: Consider bromocriptine dose reduction. (bula de Pasireotida, Interações medicamentosas)

  • BudesonidacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • Budesonida + formoterolcorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • CarvedilolbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Cetoconazolantifúngico azólicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • CiclesonidacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • CiclosporinaimunossupressorModerada

    Cyclosporine: Consider additional monitoring. (bula de Pasireotida, Interações medicamentosas)

  • CiprofloxacinofluoroquinolonaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • CitalopramISRSModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Claritromicinaantibiótico macrolídeoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • ClobetasolcorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • CloroquinaantimaláricoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • ClorpromazinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • ClozapinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • DeflazacortecorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • DesonidacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • Deutetrabenazinainibidor do VMAT2Moderada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • DexametasonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • Dextrometorfano + quinidinamedicamento serotoninérgicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Diltiazembloqueador dos canais de cálcioModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • DisopiramidaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • DofetilidaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Dorzolamida + timololinibidor da anidrase carbônicaModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • DronedaronaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Droperidolantagonista da dopaminaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Eritromicinaantibiótico macrolídeoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • EscitalopramISRSModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • EsmololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Felodipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • FingolimodeimunossupressorModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • FlecainidaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Fluconazolantifúngico azólicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • FludrocortisonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • FlunisolidacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • FluocinonidacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • FluoxetinaISRSModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • FluticasonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • Fluticasona + salmeterolcorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • Granisetronamedicamento que prolonga o intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • HalobetasolcorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • HaloperidolantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • HidrocortisonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • Hidroxicloroquinamedicamento que prolonga o intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Hidroxizinaanti-histamínicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • IbutilidaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • IloperidonaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Isradipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • LabetalolbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • LevofloxacinofluoroquinolonaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Levotiroxinahormônio tireoidianoModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (bula de Pasireotida, Advertências e precauções)

  • Levotiroxina + liotironinahormônio tireoidianoModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (bula de Pasireotida, Advertências e precauções)

  • Liotironinahormônio tireoidianoModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (bula de Pasireotida, Advertências e precauções)

  • Loperamidamedicamento que prolonga o intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • MetadonaopioideModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • MetilprednisolonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • MetoprololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Metoprolol + hidroclorotiazidabetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • MometasonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • MoxifloxacinofluoroquinolonaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • NadololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • NebivololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Nicardipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Nifedipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Nilotinibemedicamento que prolonga o intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Nimodipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Nisoldipinobloqueador dos canais de cálcio di-hidropiridínicoModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • OfloxacinofluoroquinolonaModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Olanzapina + fluoxetinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Olmesartana + anlodipino + hidroclorotiazidabloqueador do receptor da angiotensina II (BRA)Moderada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Olopatadina + mometasonaanti-histamínicoModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • Ondansetronamedicamento que prolonga o intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • PaliperidonaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Pentamidinamedicamento que prolonga o intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • PimavanserinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • PimozidaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • PindololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Pitolisantomedicamento que prolonga o intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Posaconazolantifúngico azólicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • PrednisolonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • PrednisonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • ProcainamidaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Prometazinaanti-histamínicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Prometazina + codeínaopioideModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Prometazina + dextrometorfanoanti-histamínicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Propiltiouracilamedicamento antitireoidianoModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (bula de Pasireotida, Advertências e precauções)

  • PropranololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • QuetiapinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • QuinidinaantiarrítmicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • QuininaantimaláricoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Ranolazinamedicamento que prolonga o intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • RisperidonaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • SolifenacinaanticolinérgicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • SotalolbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • TacrolimoimunossupressorModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Tamoxifenomodulador seletivo do receptor de estrogênioModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Telmisartana + anlodipinobloqueador do receptor da angiotensina II (BRA)Moderada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Teriparatidahormônio tireoidianoModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (bula de Pasireotida, Advertências e precauções)

  • Tetrabenazinainibidor do VMAT2Moderada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Tiamazol (metimazol)medicamento antitireoidianoModerada

    Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (bula de Pasireotida, Advertências e precauções)

  • TimololbetabloqueadorModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • TioridazinaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • TolterodinaanticolinérgicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Toremifenomodulador seletivo do receptor de estrogênioModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • TramadolopioideModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Tramadol + paracetamolopioideModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • TrazodonaantidepressivoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • TriancinolonacorticosteroideModerada

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (bula de Pasireotida, Advertências e precauções)

  • Trióxido de arsêniomedicamento que prolonga o intervalo QTModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Valbenazinainibidor do VMAT2Moderada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Vardenafilainibidor da PDE5Moderada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • VenlafaxinaIRSNModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • Verapamilbloqueador dos canais de cálcioModerada

    Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (bula de Pasireotida, Advertências e precauções)

  • Voriconazolantifúngico azólicoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

  • ZiprasidonaantipsicóticoModerada

    Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (bula de Pasireotida, Interações medicamentosas)

Menções leves (1)

  • ÁlcoolÁlcoolLeve

    In some reported post-marketing cases of ketoacidosis in patients taking SIGNIFOR LAR, factors predisposing to ketoacidosis such as acute illness, infection, pancreatic disorders (e.g., pancreatic malignancy or pancreatic surgery), and alcohol abuse were present. (bula de Pasireotida, Advertências e precauções)

Verifique Pasireotida com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.